Recent progress in vaccine development targeting pre-clinical human toxoplasmosis

키워드

참고문헌 (47)

1. Montoya JG, "Toxoplasmosis", Lancet, 363(9425), pp.1965~1976 (2004)[DOI]
2. Robert-Gangneux F, "Epidemiology of and diagnostic strategies for toxoplasmosis", Clin Microbiol Rev, 25(2), pp.264~296 (2012)[DOI]
3. Jones JL, "Congenital toxoplasmosis : a review", Obstet Gynecol Surv, 56(5), pp.296~305 (2001)[DOI]
4. Wang JL, "Advances in the development of anti-Toxoplasma gondii vaccines : challenges, opportunities, and perspectives", Trends Parasitol, 35(3), pp.239~253 (2019)[DOI]
5. Silva LA, "Genetic polymorphisms and phenotypic profiles of sulfadiazine-resistant and sensitive Toxoplasma gondii isolates obtained from newborns with congenital Toxoplasmosis in Minas Gerais, Brazil", PLoS One, 12(1), pp.e0170689~ (2017)[DOI]
6. Aspinall TV, "The molecular basis of sulfonamide resistance in Toxoplasma gondii and implications for the clinical management of toxoplasmosis", J Infect Dis, 185(11), pp.1637~1643 (2002)[DOI]
7. Silva LA, "Efficacy of sulfadiazine and pyrimetamine for treatment of experimental toxoplasmosis with strains obtained from human cases of congenital disease in Brazil", Exp Parasitol, 202, pp.7~14 (2019)[DOI]
8. Dubey JP, "Toxoplasmosis in sheep--the last 20 years", Vet Parasitol, 163(1-2), pp.1~14 (2009)[DOI]
9. Innes EA, "A one health approach to vaccines against Toxoplasma gondii", Food Waterborne Parasitol, 15, pp.e00053~ (2019)[DOI]
10. Havelaar AH, "World Health Organization global estimates and regional comparisons of the burden of foodborne disease in 2010", PLoS Med, 12(12), pp.e1001923~ (2015)[DOI]
11. Pollard AJ, "A guide to vaccinology : from basic principles to new developments", Nat Rev Immunol, 21(2), pp.83~100 (2021)[DOI]
12. Cyster JG, "B cell responses : cell interaction dynamics and decisions", Cell, 177(3), pp.524~540 (2019)[DOI]
13. Tang DC, "Genetic immunization is a simple method for eliciting an immune response", Nature, 356(6365), pp.152~154 (1992)[DOI]
14. Li L, "Molecular mechanisms for enhanced DNA vaccine immunogenicity", Expert Rev Vaccines, 15(3), pp.313~329 (2016)[DOI]
15. Cui Z, "DNA vaccine", Adv Genet, 54, pp.257~289 (2005)[DOI]
16. Würtele H, "Illegitimate DNA integration in mammalian cells", Gene Ther, 10(21), pp.1791~1799 (2003)[DOI]
17. Faurez F, "Biosafety of DNA vaccines : new generation of DNA vectors and current knowledge on the fate of plasmids after injection", Vaccine, 28(23), pp.3888~3895 (2010)[DOI]
18. Lee J, "Engineering DNA vaccines against infectious diseases", Acta Biomater, 80, pp.31~47 (2018)[DOI]
19. Zhu Y, "Immunization with a DNA vaccine encoding the Toxoplasma gondii’s GRA39 prolongs survival and reduce brain cyst formation in a murine model", Front Microbiol, 12, pp.630682~ (2021)[DOI]
20. Zheng B, "GRA24-based DNA vaccine prolongs survival in mice challenged with a virulent Toxoplasma gondii strain", Front Immunol, 10, pp.418~ (2019)[DOI]
21. Zheng B, "The virulencerelated MYR1 protein of Toxoplasma gondii as a novel DNA vaccine against toxoplasmosis in mice", Front Microbiol, 10, pp.734~ (2019)[DOI]
22. Sun HC, "Enhancing immune responses to a DNA vaccine encoding Toxoplasma gondii GRA7 using calcium phosphate nanoparticles as an adjuvant", Front Cell Infect Microbiol, 11, pp.787635~ (2021)[DOI]
23. Zhu YC, "Protective immunity induced by TgMIC5 and TgMIC16 DNA vaccines against toxoplasmosis", Front Cell Infect Microbiol, 11, pp.686004~ (2021)[DOI]
24. Zhang D, "Vaccination with recombinant adenoviruses expressing Toxoplasma gondii MIC3, ROP9, and SAG2 provide protective immunity against acute toxoplasmosis in mice", Vaccine, 37(8), pp.1118~1125 (2019)[DOI]
25. Zepp F, "Principles of vaccine design-Lessons from nature", Vaccine, 28(suppl), pp.C14~C24 (2010)[DOI]
26. Rosano GL, "Recombinant protein expression in Escherichia coli : advances and challenges", Front Microbiol, 5, pp.172~ (2014)[DOI]
27. Ducker C, "Comparative analysis of protein expression systems and PTM landscape in the study of transcription factor ELK-1", Protein Expr Purif, 203, pp.106216~ (2022)[DOI]
28. D’Amico C, "Development of vaccine formulations : past, present, and future", Drug Deliv Transl Res, 11(2), pp.353~372 (2021)[DOI]
29. Zhao G, "Immunization with Toxoplasma gondii aspartic protease 3 increases survival time of infected mice", Acta Trop, 171, pp.17~23 (2017)[DOI]
30. Fereig RM, "Immunization with Toxoplasma gondii peroxiredoxin 1induces protective immunity against toxoplasmosis in mice", PLoS One, 12(4), pp.e0176324~ (2017)[DOI]
31. Liu F, "Protective effect against toxoplasmosis in BALB", c mice vaccinated with recombinant Toxoplasma gondii MIF, CDPK3, and 14-3-3 protein cocktail vaccine, 2021, pp.12, 755792~
32. Chu KB, "Virus-like particle vaccines against respiratory viruses and protozoan parasites", Curr Top Microbiol Immunol, 433, pp.77~106 (2021)[DOI]
33. Bachmann MF, "The influence of antigen organization on B cell responsiveness", Science, 262(5138), pp.1448~1451 (1993)[DOI]
34. Brune KD, "New routes and opportunities for modular construction of particulate vaccines : stick, click, and glue", Front Immunol, 9, pp.1432~ (2018)[DOI]
35. Manolova V, "Nanoparticles target distinct dendritic cell populations according to their size", Eur J Immunol, 38(5), pp.1404~1413 (2008)[DOI]
36. Bachmann MF, "Vaccine delivery : a matter of size, geometry, kinetics and molecular patterns", Nat Rev Immunol, 10(11), pp.787~796 (2010)[DOI]
37. Lee SH, "Protection induced by virus-like particles containing Toxoplasma gondii microneme protein 8 against highly virulent RH strain of Toxoplasma gondii infection", PLoS One, 12(4), pp.e0175644~ (2017)[DOI]
38. 강해지, "Virus-like Particle Vaccine Containing Toxoplasma gondii Rhoptry Protein 13 Induces Protection against T. gondii ME49 Infection in Mice", Parasites, Hosts and Diseases, 57(5), pp.543~547 (2019), 대한기생충학ㆍ열대의학회[DOI]
39. 강해지, "Virus-Like Particles Expressing Toxoplasma gondii Rhoptry Protein 18 Induces Better Protection Than Rhoptry Protein 4 against T. gondii Infection", Parasites, Hosts and Diseases, 56(5), pp.429~435 (2018), 대한기생충학ㆍ열대의학회
40. Kang HJ, "Toxoplasma gondii virus-like particle vaccination alleviates inflammatory response in the brain upon T. gondii infection", Parasite Immunol, 42(6), pp.e12716~ (2020)[DOI]
41. Kang HJ, "Influenza virus-like particles presenting both Toxoplasma gondii ROP4and ROP13 enhance protection against T. gondii infection", Pharmaceutics, 11(7), pp.342~ (2019)[DOI]
42. Lee SH, "Virus-like particle vaccines expressing Toxoplasma gondii rhoptry protein 18 and microneme protein 8 provide enhanced protection", Vaccine, 36(38), pp.5692~5700 (2018)[DOI]
43. Lee SH, "Protective immunity induced by incorporating multiple antigenic proteins of Toxoplasma gondii into influenza virus-like particles", Front Immunol, 9, pp.3073~ (2018)[DOI]
44. Lee SH, "Virus-like particles containing multiple antigenic proteins of Toxoplasma gondii induce memory T cell and B cell responses", PLoS One, 14(8), pp.e0220865~ (2019)[DOI]
45. Guo J, "Immunogenicity of a virus-like-particle vaccine containing multiple antigenic epitopes of Toxoplasma gondii against acute and chronic toxoplasmosis in mice", Front Immunol, 10, pp.592~ (2019)[DOI]
46. Kang HJ, "Protective immunity induced by CpG ODN-adjuvanted virus-like particles containing Toxoplasma gondii proteins", Parasite Immunol, 43(1), pp.e12799~ (2021)[DOI]
47. Kang HJ, "Evaluation of CpG-ODN-Adjuvanted Toxoplasma gondii virus-like particle vaccine upon one, two, and three immunizations", Pharmaceutics, 12(10), pp.989~ (2020)[DOI]

관련 논문AI추천